News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

American Society of Clinical Oncology 2013: Boehringer Ingelheim Pharmaceuticals, Inc. to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC


5/16/2013 9:55:28 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced the upcoming presentation of data from 14 abstracts involving three of the company's investigational oncology compounds – afatinib*, nintedanib* and volasertib*. Results – to be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2013 – are from Boehringer Ingelheim's robust oncology pipeline and demonstrate the company's commitment to the oncology community and patients through the research and development of new anti-cancer compounds.

Help employers find you! Check out all the jobs and post your resume.

Read at PR Newswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES